{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:17:05Z","timestamp":1787876225725,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060572"],"award-info":[{"award-number":["82060572"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Technologies Research and Development Program of ningxia","award":["No. 2019BFG02008"],"award-info":[{"award-number":["No. 2019BFG02008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01181-5","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T08:01:15Z","timestamp":1716710475000},"page":"1659-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-1637","authenticated-orcid":false,"given":"Huijuan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,26]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","volume":"361","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M. Psoriasis. Lancet. 2003;361:1197\u2013204.","journal-title":"Lancet"},{"key":"1181_CR2","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/09546634.2019.1689228","volume":"32","author":"KA Reynolds","year":"2021","unstructured":"Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatolog Treat. 2021;32:49\u201355.","journal-title":"J Dermatolog Treat"},{"key":"1181_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","volume":"62","author":"M Rosenbach","year":"2010","unstructured":"Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62:655\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaad.2020.03.073","volume":"83","author":"OY Carrasquillo","year":"2020","unstructured":"Carrasquillo OY, Pab\u00f3n-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83:151\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/09546634.2018.1430301","volume":"29","author":"N AlMutairi","year":"2018","unstructured":"AlMutairi N, Abouzaid HA. Safety of biologic agents for psoriasis in patients with viral hepatitis. J Dermatolog Treat. 2018;29:553\u20136.","journal-title":"J Dermatolog Treat"},{"key":"1181_CR7","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","volume":"22","author":"C Bonifati","year":"2016","unstructured":"Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis\u00a0B or hepatitis\u00a0C virus infection. World J Gastroenterol. 2016;22:6444\u201355.","journal-title":"World J Gastroenterol"},{"key":"1181_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1142\/S0192415X14500359","volume":"42","author":"CY Wang","year":"2014","unstructured":"Wang CY, Bai XY, Wang CH. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med. 2014;42:543\u201359.","journal-title":"Am J Chin Med"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"373219","DOI":"10.1155\/2012\/373219","volume":"2012","author":"M Sun","year":"2012","unstructured":"Sun M, Cao H, Sun L, et al. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med. 2012;2012:373219.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1181_CR10","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3748\/wjg.v9.i11.2480","volume":"9","author":"LG Lu","year":"2003","unstructured":"Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis\u00a0B: a randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol. 2003;9:2480\u20133.","journal-title":"World J Gastroenterol"},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/s0102-865020180030000002","volume":"33","author":"J Wu","year":"2018","unstructured":"Wu J, Pan L, Jin X, et al. The role of oxymatrine in regulating TGF-\u03b21 in rats with hepatic fibrosis. Acta Cir Bras. 2018;33:207\u201315.","journal-title":"Acta Cir Bras"},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"105565","DOI":"10.1016\/j.fitote.2023.105565","volume":"168","author":"DQ Huan","year":"2023","unstructured":"Huan DQ, Hop NQ, Son NT. Oxymatrine: a current overview of its health benefits. Fitoterapia. 2023;168:105565.","journal-title":"Fitoterapia"},{"key":"1181_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013482","volume":"97","author":"X Jiang","year":"2018","unstructured":"Jiang X, Xie L, Huang C, et al. Oral oxymatrine for hepatitis\u00a0B cirrhosis: a systematic review protocol. Medicine (Baltimore). 2018;97:e13482.","journal-title":"Medicine (Baltimore)"},{"key":"1181_CR14","first-page":"597","volume":"12","author":"LG Lu","year":"2004","unstructured":"Lu LG, Zeng MD, Mao YM, et al. Oxymatrine in the treatment of chronic hepatitis\u00a0B for one year: a multicenter random double-blind placebo-controlled trial. Zhonghua Gan Zang Bing Za Zhi. 2004;12:597\u2013600.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"1181_CR15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3736\/jcim20090806","volume":"7","author":"WX Zhou","year":"2009","unstructured":"Zhou WX, Zheng WB, Huang XM, et al. Effects of oxymatrine on microinflammatory state in patients undergoing continuous hemodialysis: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2009;7:736\u201340.","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"1181_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1159\/000480471","volume":"43","author":"YY Zhang","year":"2017","unstructured":"Zhang YY, Yi M, Huang YP. Oxymatrine ameliorates doxorubicin-induced cardiotoxicity in rats. Cell Physiol Biochem. 2017;43:626\u201335.","journal-title":"Cell Physiol Biochem"},{"key":"1181_CR17","first-page":"217","volume":"118","author":"H Ozturk","year":"2017","unstructured":"Ozturk H, Cetinkaya A, Yilmaz F, Ozturk H. Protective effect of oxymatrine against renal ischemia\/reperfusion injury in rats. Bratisl Lek Listy. 2017;118:217\u201322.","journal-title":"Bratisl Lek Listy"},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/bjd.15316","volume":"176","author":"H Zhou","year":"2017","unstructured":"Zhou H, Shi HJ, Yang J, et al. Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial. Br J Dermatol. 2017;176:1446\u201355.","journal-title":"Br J Dermatol"},{"key":"1181_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/JIR.S402535","volume":"16","author":"X Xue","year":"2023","unstructured":"Xue X, Guo Y, Zhao Q, et al. Weighted gene co-expression network analysis of oxymatrine in psoriasis treatment. J Inflamm Res. 2023;16:845\u201359.","journal-title":"J Inflamm Res"},{"key":"1181_CR20","doi-asserted-by":"publisher","first-page":"889493","DOI":"10.3389\/fphar.2022.889493","volume":"13","author":"X Xue","year":"2022","unstructured":"Xue X, Yu J, Li C, et al. Full-length transcriptome sequencing analysis of differentially expressed genes and pathways after treatment of psoriasis with oxymatrine. Front Pharmacol. 2022;13:889493.","journal-title":"Front Pharmacol"},{"key":"1181_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bjd.17852","volume":"181","author":"HJ Shi","year":"2019","unstructured":"Shi HJ, Zhou H, Ma AL, et al. Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis. Br J Dermatol. 2019;181:1028\u201337.","journal-title":"Br J Dermatol"},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjd.18299","volume":"181","author":"G Groma","year":"2019","unstructured":"Groma G. Oxymatrine may represent an additional therapeutic tool in severe plaque psoriasis management. Br J Dermatol. 2019;181:891\u20132.","journal-title":"Br J Dermatol"},{"key":"1181_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1046\/j.1365-4362.2000.00017.x","volume":"39","author":"M Harari","year":"2000","unstructured":"Harari M, Shani J, Hristakieva E, et al. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and severity index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol. 2000;39:913\u20138.","journal-title":"Int J Dermatol"},{"key":"1181_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130:933\u201343.","journal-title":"J Invest Dermatol"},{"key":"1181_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1181_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961\u20139.","journal-title":"JAMA Dermatol"},{"key":"1181_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1590\/abd1806-4841.20176565","volume":"92","author":"LA Tr\u00eddico","year":"2017","unstructured":"Tr\u00eddico LA, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11\u00a0years in a patient with erythrodermic psoriasis and psoriatic arthritis. An Bras Dermatol. 2017;92:743\u20135.","journal-title":"An Bras Dermatol"},{"key":"1181_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.apsb.2017.02.005","volume":"7","author":"X Sang","year":"2017","unstructured":"Sang X, Wang R, Han Y, et al. T\u00a0cell-associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model. Acta Pharm Sin B. 2017;7:311\u20138.","journal-title":"Acta Pharm Sin B"},{"key":"1181_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1572-0241.2002.05581.x","volume":"97","author":"C Kreiss","year":"2002","unstructured":"Kreiss C, Amin S, Nalesnik MA, Chopra K, Shakil AO. Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol. 2002;97:775\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1181_CR30","doi-asserted-by":"publisher","first-page":"115209","DOI":"10.1016\/j.taap.2020.115209","volume":"405","author":"X Xiang","year":"2020","unstructured":"Xiang X, Tu C, Li Q, et al. Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes. Toxicol Appl Pharmacol. 2020;405:115209.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1181_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ajd.12895","volume":"60","author":"M Rademaker","year":"2019","unstructured":"Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol. 2019;60:91\u20138.","journal-title":"Australas J Dermatol"},{"key":"1181_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","volume":"36","author":"P Gisondi","year":"2018","unstructured":"Gisondi P, Fostini AC, Foss\u00e0 I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36:21\u20138.","journal-title":"Clin Dermatol"},{"key":"1181_CR33","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Prim. 2016;2:16082.","journal-title":"Nat Rev Dis Prim"},{"key":"1181_CR34","doi-asserted-by":"publisher","first-page":"1340677","DOI":"10.3389\/fimmu.2023.1340677","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Lu J, Liu J, et al. Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets. Front Immunol. 2023;14:1340677.","journal-title":"Front Immunol"},{"key":"1181_CR35","doi-asserted-by":"publisher","first-page":"223ra22","DOI":"10.1126\/scitranslmed.3007217","volume":"6","author":"GK Perera","year":"2014","unstructured":"Perera GK, Ainali C, Semenova E, et al. Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci Transl Med. 2014;6:223ra22.","journal-title":"Sci Transl Med"},{"key":"1181_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","volume":"9","author":"L Mercurio","year":"2018","unstructured":"Mercurio L, Morelli M, Scarponi C, et al. IL-38\u00a0has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018;9:1104.","journal-title":"Cell Death Dis"},{"key":"1181_CR37","doi-asserted-by":"publisher","first-page":"819149","DOI":"10.1155\/2015\/819149","volume":"2015","author":"PS de Oliveira","year":"2015","unstructured":"de Oliveira PS, Cardoso PR, Lima EV, et al. IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediat Inflamm. 2015;2015:819149.","journal-title":"Mediat Inflamm"},{"key":"1181_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","volume":"71","author":"CW Lynde","year":"2014","unstructured":"Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1181_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1142\/S0192415X20500275","volume":"48","author":"YY Xu","year":"2020","unstructured":"Xu YY, Wang DM, Liang HS, et al. The role of Th17\/Treg axis in the traditional chinese medicine intervention on immune-mediated inflammatory diseases: a systematic review. Am J Chin Med. 2020;48:535\u201358.","journal-title":"Am J Chin Med"},{"key":"1181_CR40","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.phrs.2019.104541","volume":"151","author":"X Lan","year":"2020","unstructured":"Lan X, Zhao J, Zhang Y, et al. Oxymatrine exerts organ- and tissue-protective effects by regulating inflammation, oxidative stress, apoptosis, and fibrosis: from bench to bedside. Pharmacol Res. 2020;151:104541.","journal-title":"Pharmacol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:04:39Z","timestamp":1718197479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01181-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,26]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (Huijuan Shi, Dongmei Chen, Jiawei Si, Qian Zou, Yatao Guo, Jiayu Yu, Cheng Li, and Fang Wang) have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Ethics Committee of General Hospital of Ningxia Medical University (Approval No. 2018-352). Each patient and volunteer provided written informed consent. Permission was obtained to publish the patient images in this study. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}